Autism research at the crossroads
By Brady Huggett,
Spectrum News
| 01. 25. 2023
In April of 2021, Emilie Wigdor finished up a paper titled “The female protective effect against autism spectrum disorder” and put it on the pre-print server medRxiv. Wigdor is a Ph.D. student in human genetics at the University of Cambridge and the Wellcome Sanger Institute in the United Kingdom, and the paper had taken three years to complete. It was also the first paper on which she was first author. She was proud of that, and she took to Twitter to promote the work in an 11-part thread.
Wigdor isn’t particularly active on the platform; she mostly retweets, and she has just hundreds of followers, many of whom are geneticists and researchers like her. A handful of them offered admiring comments in replies to her post. But when the paper was published in the peer-reviewed Cell Genomics in June 2022 and she put out a similar 11-tweet thread on 8 June, the response was quite different.
This time, one of the first replies was from an autistic researcher in Australia, who tagged Ann Memmott and pointed to Wigdor’s thread as...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...